U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H21N6O7S2.H.5H2O
Molecular Weight 636.652
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFTAZIDIME

SMILES

[H+].O.O.O.O.O.[H][C@]12SCC(C[N+]3=CC=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C([O-])=O)\C4=CSC(N)=N4)C([O-])=O

InChI

InChIKey=NMVPEQXCMGEDNH-TZVUEUGBSA-N
InChI=1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13-;;;;;/t14-,18-;;;;;/m1...../s1

HIDE SMILES / InChI
Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C22H21N6O7S2
Molecular Weight 545.568
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Description

Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-stream, joint, and abdominal infections, and meningitis. The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the patient. Injectable formulations of ceftazidime are currently nebulized "off-label" to manage Cystic Fibrosis, non-Cystic Fibrosis bronchiectasis, drug-resistant nontuberculous mycobacterial infections, ventilator-associated pneumonia, and post-transplant airway infections. Ceftazidime is generally well-tolerated. When side effects do occur, they are most commonly local effects from the intravenous line site, allergic reactions, and gastrointestinal symptoms. According to one manufacturer, in clinical trials, allergic reactions including itching, rash, and fever, happened in fewer than 2% of patients. Rare but more serious allergic reactions, such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme, have been reported with this class of antibiotics, including ceftazidime. Gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain, were reported in fewer than 2% of patients.

CNS Activity

Originator

Approval Year

1985
117
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Inhibitor
8297
Inhibitor
8297
Inhibitor
8297
Inhibitor
8297
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
FORTAZ

Approved Use

Ceftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime for injection, USP has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime for injection, USP has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1985
Curative
Approved
8429
FORTAZ

Approved Use

Ceftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime for injection, USP has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime for injection, USP has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1985
Curative
Approved
8429
FORTAZ

Approved Use

Ceftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime for injection, USP has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime for injection, USP has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1985
Primary
Phase IV
63
FORTAZ

Approved Use

Ceftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime for injection, USP has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Ceftazidime for injection, USP may be used alone in cases of confirmed or suspected sepsis. Ceftazidime for injection, USP has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. Ceftazidime for injection, USP may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, USP and other antibacterial drugs, ceftazidime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1985
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
21.3 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2088186
75 mg/kg other, intravenous
dose: 75 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
CEFTAZIDIME serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
18 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2088186
75 mg/kg 1 times / day other, intravenous
dose: 75 mg/kg
route of administration: Intravenous
experiment type: OTHER
co-administered:
CEFTAZIDIME unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
285 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2088186
25 mg/kg 3 times / day multiple, intravenous
dose: 25 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CEFTAZIDIME serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.6 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/2088186
25 mg/kg 3 times / day multiple, intravenous
dose: 25 mg/kg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CEFTAZIDIME serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 g 3 times / day multiple, intravenous
Highest studied dose
Dose: 1 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 3 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050578s061,050634s028lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Condition: pneumonia
Age Group: adult
Sex: unknown
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050578s061,050634s028lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050578s061,050634s028lbl.pdf
300 mg/kg 14 times / day multiple, intravenous
Highest studied dose
Dose: 300 mg/kg, 14 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/kg, 14 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8821302/
unhealthy, children
n = 15
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: children
Sex: unknown
Population Size: 15
Sources:
https://pubmed.ncbi.nlm.nih.gov/8821302/
Other AEs: Urticaria, Itchy rash...
Other AEs:
Urticaria (3 patients)
Itchy rash (4 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8821302/
AEs

AEs

AESignificanceDosePopulation
Urticaria 3 patients
300 mg/kg 14 times / day multiple, intravenous
Highest studied dose
Dose: 300 mg/kg, 14 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/kg, 14 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8821302/
unhealthy, children
n = 15
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: children
Sex: unknown
Population Size: 15
Sources:
https://pubmed.ncbi.nlm.nih.gov/8821302/
Itchy rash 4 patients
300 mg/kg 14 times / day multiple, intravenous
Highest studied dose
Dose: 300 mg/kg, 14 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/kg, 14 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8821302/
unhealthy, children
n = 15
Health Status: unhealthy
Condition: cystic fibrosis
Age Group: children
Sex: unknown
Population Size: 15
Sources:
https://pubmed.ncbi.nlm.nih.gov/8821302/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
inhibitor
1767
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1461

BCRP
699

OATP1B1
788

OATP1B3
706

OCT1
512

OCT2
647

OAT1
599

OAT3
642

MRP3
157

BSEP
402
CYP1A2
1054

CYP2B6
664

UGT1A1
418

P-gp
1537

BCRP
561

OATP1B1
406

OATP1B3
350

OCT1
327

OCT2
355

OAT1
326

OAT3
339

MRP3
50

BSEP
52
CYP
76
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BCRP
773
 no
BSEP
403
 no
CYP
147
 no
CYP2C9
1819
 no
MRP3
207
 no
OAT1
603
 no
OAT3
644
 no
OATP1B1
803
 no
OATP1B3
715
 no
OCT1
543
 no
OCT2
648
 no
P-gp
1650
 no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
561
 inconclusive
BSEP
52
 inconclusive
MRP3
50
 inconclusive
OAT1
326
 inconclusive
OAT3
339
 inconclusive
OATP1B1
406
 inconclusive
OATP1B3
350
 inconclusive
OCT1
327
 inconclusive
OCT2
355
 inconclusive
P-gp
1537
 inconclusive
UGT1A1
418
 inconclusive
CYP1A2
1054
 no
CYP2B6
664
 no
CYP3A4
1737
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00IKZD
A2B Chem
AI66201
AK Scientific
9619AJ
AK Scientific
E115
AK Scientific
G174
AbovChem LLC
HY-B0593
Alfa Chemistry
223351
Alfa Chemistry
ACM73547703
Angene
AGN-PC-0WHB0Y
ApexBio Technology
B3539
AstaTech
42417
AstaTech
42446
AstaTech
C16303
BOC Sciences
72558-82-8
BOC Sciences
78439-06-2
Bide Pharmatech
BD120321
BioSynth
Q-200813
Bosche Scientific
C2791
Cayman Chemical
14828
Chem Scene
CS-2810
Chem-Impex International
2879
Compound Cloud
5481173
Compound Cloud
6321415
Compound Cloud
6536864
Hairui
HR126019
Hairui
HR127562
Hairui
HR131790
Hangzhou APIChem Technology
AC-18971
Hangzhou APIChem Technology
AC-18972
Hangzhou Yuhao Chemical Technology
LT7093
KeyOrganics
AS-75297
Lab Network
249
MedChem Express
HY-B0593
MolPort
MolPort-003-698-286
MolPort
MolPort-006-137-763
MolPort
MolPort-020-001-272
MolPort
MolPort-044-183-269
MolPort
MolPort-046-588-802
Molnova
M15778
PI Chemicals
PI-10779
PI Chemicals
PI-38675
Ryan Scientific
Iohexol
Sigma Aldrich
A6987
Sigma Aldrich
A6987|SIGMA
Sigma Aldrich
C3809
Sigma Aldrich
C3809|SIGMA
Sigma Aldrich
CDS020667
TargetMol
T1305
Tetrahedron
TS75058
Toronto Research Chemicals
C244100
Toronto Research Chemicals
C244128
Vitas-M Laboratory
STK047059
W&J PharmaChem
100160
Wonderchem
WC-009UYU
ZINC
ZINC000003871960
http://zinc15.docking.org/substances/ZINC000003871960
ZINC
ZINC000008035456
http://zinc15.docking.org/substances/ZINC000008035456
ZINC
ZINC000008582317
http://zinc15.docking.org/substances/ZINC000008582317
ZINC
ZINC000254846637
http://zinc15.docking.org/substances/ZINC000254846637
ZINC
ZINC000254846639
http://zinc15.docking.org/substances/ZINC000254846639
eMolecules
193065907
eMolecules
301160656
eMolecules
313121473
eMolecules
48600981
eMolecules
50241616
mcule
MCULE-1860404300
mcule
MCULE-5264603916
mcule
MCULE-9068634681
PubMed

PubMed

TitleDatePubMed
Renal tolerance of ceftazidime in animals.
1981 Sep
Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae type b.
1984 Jan
Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia.
1987 Apr 27
Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction.
1991
Animal models as predictors of outcome of therapy with broad spectrum cephalosporins.
1992 Apr
Ceftazidime encephalopathy: absence status and toxic hallucinations.
1992 Apr
Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis.
1993 Mar
Neurotoxicity associated with intraperitoneal ceftazidime therapy in a CAPD patient.
1994
[Acute interstitial nephritis. Role of ceftazidime].
1996
Mania due to clarithromycin therapy in a patient who was not infected with human immunodeficiency virus.
1996 Mar
[Analysis of the etiologic structure of urinary tract infection and antibiotic-resistance of its pathogens].
1997
QT prolongation and Torsades de Pointes associated with clarithromycin.
1998 Apr
[Basic and clinical studies on tazobactam/piperacillin in pediatric field].
1998 Jun
[Fatal encephalopathy induced by ceftazidime].
1998 Nov-Dec
Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure.
2001 Aug
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Meningitis caused by Enterococcus gallinarum in patients with ventriculoperitoneal shunts.
2003 Dec
Acute renal failure and cystic fibrosis.
2003 Jul
Retrospective review of neurotoxicity induced by cefepime and ceftazidime.
2003 Mar
Correlation between candiduria and departmental antibiotic use.
2003 Mar
Creutzfeldt-Jakob-like EEG in a patient with end-stage renal failure.
2004 Jan
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
CR5/20--Acute renal failure in a child with cystic fibrosis awaiting lung transplantation--a good outcome after all.
2006
Disseminated invasive aspergillosis in a patient with acute leukaemia.
2006
Cephalosporin-induced myoclonus.
2006 Mar 28
Antibiotics modulate the stimulated cytokine response to endotoxin in a human ex vivo, in vitro model.
2006 Oct
One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia--a new paradigm.
2007 Apr
Adverse drug reactions in medical intensive care unit of a tertiary care hospital.
2009 Jul
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Patents

JP2001500477A
122
JP2002511777A
414
JP2002541233A
400
JP2002542249A
12
JP2003515526A
462
JP2005298525A
5
JP2009541210A
79
JP2010507658A
34
JP2011207900A
5
JP2011528275A
455
JP4718445B2
36
JP4722295B2
104
JP4763957B2
87
JP4787165B2
101
JP4792032B2
112
JP4849764B2
75
JPH01308284A
5
JPH02215786A
5
JPH069647A
5
JPH08283272A
5
JPH10115610A
5
JPH10127275A
5
JPS0667413A
9
JPS6067413A
9
JPS6110591A
5
JPS61115088A
5
JPS6115885A
5
JPS6118786A
5
JPS6137728A
5

Sample Use Guides

In Vivo Use Guide
The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection, and the condition and renal function of the patient.
Route of Administration: Other
In Vitro Use Guide
Ceftazidime–avibactam and comparator antibacterial agents were tested by reference broth microdilution against 417non-repetitive Gram-negative bacilli (387 unselected, plus 30selected blaKPC-positive, meropenem – nonsusceptible, Kleb-siella pneumoniae) collected prospectively from medical centersat Hospital das Clínicas da Faculdade de Medicina da Uni-versidade de São Paulo, Brazil, in 2014 and 2015. Minimum inhibitory concentrations (MICs), one per isolate, were determined by reference Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods using frozen microtiter plates pre-loaded with antibiotic-containing growth medium. MICs ofceftazidime–avibactam were measured by varying the concen-tration of ceftazidime in twofold increments with avibactamat a fixed concentration of 4 mg/L. Addition of avibactam at 4 mg/L decreased MICs of cef-tazidime against unselected Enterobacteriaceae, especially K.pneumoniae, Citrobacter freundii, and Enterobacter cloacae, among which MIC90values decreased from 128 to >128 mg/L to0.5–4 mg/L. Among the unselected isolates of these three species 37–73% were susceptible to ceftazidime, whereas 100%were susceptible to ceftazidime–avibactam.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:15:29 GMT 2023
Edited
by admin
on Fri Dec 15 15:15:29 GMT 2023
Record UNII
9M416Z9QNR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFTAZIDIME
DASH   ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
LY 139381
Code English
CEPTAZ
Brand Name English
LY-139381
Code English
CEFTAZIDIME PENTAHYDRATE
EP   MI   USP-RS   WHO-DD  
Common Name English
CEFTAZIDIME [ORANGE BOOK]
Common Name English
Ceftazidime pentahydrate [WHO-DD]
Common Name English
CEFTAZIDIME HYDRATE [JAN]
Common Name English
CEFTAZIDIME [USAN]
Common Name English
FORTAZ
Brand Name English
PENTACEF
Brand Name English
ZAVICEFTA COMPONENT CEFTAZIDIME
Brand Name English
CEFTAZIDIME PENTAHYDRATE [EP MONOGRAPH]
Common Name English
GR 20263
Code English
1-(((6R,7R)-7-(2-(2-AMINO-4-THIAZOLYL)GLYOXYLAMIDO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)PYRIDINIUM HYDROXIDE INNER SALT 7(SUP 2)-(Z)-(O-(1-CARBOXY-1-METHYLETHYL)OXIME), PENTAHYDRATE
Common Name English
CEFTAZIDIME COMPONENT OF ZAVICEFTA
Brand Name English
CEFTAZIDIME COMPONENT OF AVYCAZ
Brand Name English
CEFTAZIDIME PENTAHYDRATE [MI]
Common Name English
TAZIDIME
Brand Name English
AVYCAZ COMPONENT CEFTAZIDIME
Brand Name English
TAZICEF
Brand Name English
CEFTAZIDIME PENTAHYDRATE [USP-RS]
Common Name English
J01DD07
Code English
CEFTAZIDIME [VANDF]
Common Name English
CEFTAZIDIME [USP MONOGRAPH]
Common Name English
GR-20263
Code English
PYRIDINIUM, 1-((7-(((2-AMINO-4-THIAZOLYL)((1-CARBOXY-1-METHYLETHOXY)IMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-, HYDROXIDE, INNER SALT, PENTAHYDRATE, (6R-(6.ALPHA.,7.BETA.(Z)))-
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
WHO-VATC QJ01DD02
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
NDF-RT N0000175488
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
LIVERTOX NBK548666
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
WHO-ATC J01DD52
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
WHO-ATC J01DD02
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
LIVERTOX NBK547862
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
NCI_THESAURUS C357
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1098130
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
SMS_ID
100000084683
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
USAN
R-101
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
EVMPD
SUB01134MIG
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
CHEBI
3509
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
MESH
D002442
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
LACTMED
Ceftazidime
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
CAS
78439-06-2
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
RXCUI
235552
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
NCI_THESAURUS
C66868
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID0045599
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
WIKIPEDIA
CEFTAZIDIME
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
CHEBI
3508
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
MERCK INDEX
m3218
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY Merck Index
RXCUI
2191
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
ALTERNATIVE
DAILYMED
9M416Z9QNR
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
PUBCHEM
6536864
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
LACTMED
Ceftazidime and Avibactam
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
DRUG BANK
DB00438
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL44354
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
FDA UNII
9M416Z9QNR
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
DRUG CENTRAL
559
Created by admin on Fri Dec 15 15:15:29 GMT 2023 , Edited by admin on Fri Dec 15 15:15:29 GMT 2023
PRIMARY
Related Record Type Details
Structure of CEFTAZIDIME ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Structure of CEFTAZIDIME ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of CEFTAZIDIME ANHYDROUS
ANHYDROUS->SOLVATE
Structure of CEFTAZIDIME ANHYDROUS
PARENT -> SALT/SOLVATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of CEFTAZIDIME ANHYDROUS, (E)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-[[(Z)-[1-(2-Amino-4-thiazolyl)-2-oxo-2-[(2-oxoethyl)amino]ethylidene]amino]oxy]-2-methylpropanoic acid
IMPURITY -> PARENT
For the calculation of content, multiply the peak area of by 3.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of PYRIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of CEFTAZIDIME ANHYDROUS
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966